Fulgent Genetics, Inc.

Health Care
Medical Specialities
www.fulgentgenetics.com

Earnings Score
Moat Score
Safety Score

Market Cap $631.69M
PE -4
Debt $412.00K
Cash $58.18M
EV $573.93M
FCF -$28.67M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$171.96M
EBIT	-$189.11M
ROE	-15%
ROA	-15%
FCF	-$28.67M
Equity	$1.14B
Growth Stability	-61%
PE	-3.67
PEG	-0.48
PB	0.55
P/FCF	-22.03
P/S	2.27
Price/Cash	0.09
Debt/Equity	0
Debt/FCF	-0.01
Net Margins	-18%
Gross Margins	36%
Op. Margins	-68%
Earnings CAGR	1%
Sales Growth YoY	-15%
Sales Growth QoQ	1%
Sales CAGR	71%
FCF CAGR	34%
Equity CAGR	80%
Earnings Stability	0
Earnings Growth YoY	9%
Earnings Growth QoQ	62%

Earnings CAGR 5Y	8%
Sales CAGR 5Y	32%
FCF CAGR 5Y	-17%
Equity CAGR 5Y	68%
Earnings CAGR 3Y	-43%
Sales CAGR 3Y	-43%
FCF CAGR 3Y	-85%
Equity CAGR 3Y	-4%
Market Cap	$631.69M
Revenue	$277.76M
Assets	$1.23B
Total Debt	$412.00K
Cash	$58.18M
Shares Outstanding	30.1M
EV	573.93M
Earnings Score	6%
Moat Score	4%
Safety Score	34%
Final Score	15%
Working Capital	252.55M
Current Ratio	4.41
Gross Profit	$100.60M
Shares Growth 3y	0%
Equity Growth QoQ	1%
Equity Growth YoY	-10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

SEC Filings

Direct access to Fulgent Genetics, Inc. (FLGT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Fulgent Genetics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Fulgent Genetics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%

Stability 0%

loading chart...

Fulgent Genetics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Fulgent Genetics, Inc..

Years

Calculation mode

= -$3.1B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$29M	-$38M	-$52M	-$69M	-$93M	-$125M	-$168M	-$225M	-$302M	-$405M	-$544M	-$5.4B
DCF		-$35M	-$43M	-$52M	-$64M	-$78M	-$95M	-$115M	-$141M	-$172M	-$210M	-$2.1B
Value	-$3.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-335%	-87%	-75%	-13%	-26%	-1%	51%	51%	23%	-61%	-18%
ROA	-	-85%	2%	-6%	-9%	0%	42%	53%	13%	-14%	-15%
ROE	-	-14%	-25%	-5%	-11%	-0%	38%	43%	11%	-15%	-15%

Bad Net Margins (-18.16%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	0.01	0.02	0.25	-0.01
Debt over Equity	-	-	-	-	-	-	-	0.01	0	0	0
Growth Stability	-	-	-	-	-	-	-	100%	59%	-61%	-61%

Good Debt/FCF ratio (-0.01)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-61%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	649%	91%	2%	14%	52%	1K%	135%	-38%	-53%	32%
Earnings YoY growth	-	94%	64%	-82%	123%	-93%	-52K%	136%	-72%	-223%	8%
Equity YoY growth	-	3K%	-7%	-1%	-6%	62%	588%	105%	9%	-11%	68%
FCF YoY growth	-	-96%	-976%	-341%	92%	-245%	2K%	388%	-54%	-98%	-17%